Pharmaceutical

GT Biopharma announced it made the payment for the license of PainBrake, a non-opioid medication from Accu-Break Pharmaceuticals, which the company plans to develop.

GT Biopharma (OTCQB:OXISD) announced it made the payment for the license of PainBrake, a non-opioid medication from Accu-Break Pharmaceuticals, which the company plans to develop.
As quoted in the press release:

The payment allows GT Biopharma to begin the clinical development process and the filing of a New Drug Application, the final step for a commercial license from the Food and Drug Administration. The company expects to submit an NDA for PainBrake within 18 months.
PainBrake will use a patented technology – and unique shape – that allows tablets to be easily broken into smaller, precise doses, for maximum dose flexibility and accuracy. The top layer contains the pain-killer and is pre-divided by deep scoring during the manufacturing process to provide exact doses.

Click here to read the full press release.

Source: www.accesswire.com

MARKETS

Markets
TSX19620.13+43.09
TSXV664.17+4.09
DOW32803.47+76.65
S&P 5004145.19-6.75
NASD12657.55-63.03
ASX6974.90-1.00

COMMODITIES

Commodities
Gold1774.96-18.13
Silver19.90-0.30
Copper3.55+0.07
Palladium2124.59+60.59
Platinum936.51+5.51
Oil88.53-0.01
Heating Oil3.20-0.13
Natural Gas8.01-0.12

DOWNLOAD FREE REPORTS

×